Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Open accessThe DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Abstract
Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Systemic approaches to stimulating innate immunity, such as via agonism of stimulator of interferon response cGAMP interactor 1 (STING) or Toll-like receptors (TLR), have been challenging (199)(200)(201).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [201]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citationType I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667 · cited 1×
“Conversely, TLR3 obligatorily drives cytokine synthesis via toll like receptor adaptor molecule 1 (TICAM1, best known as TRIF).(67,68)”
BackgroundDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Type I interferon-mediated tumor immunity and its role in immunotherapy
Yu, R., Zhu, B., & Chen, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04219-z · Cited by 309
“cancer have shown disappointing results in recent clinical tests [76, 81, 82].”
ResultTargeting cancer with antibody-drug conjugates: Promises and challenges
Dean, A. Q., Luo, S., Twomey, J. D., & Zhang, B. (2021) · mAbs · doi:10.1080/19420862.2021.1951427 · Cited by 190
Metadata
- Authors
- Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O.
- Affiliations
- Inserm (FR)
- Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers
- Université Paris Cité (FR)
- Karolinska University Hospital (SE)
- Corresponding author
- Kroemer, Guido
- Kepp, Oliver
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 1796002-1796002
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC7466852
- OpenAlex
- W3045299854
- Cited by
- 108
- References
- 147
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 24 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Defense (#BC180476P1)
- Leukemia and Lymphoma Society
- Association pour la Recherche sur le Cancer (ANR-18-IDEX-0001)
- Seerave Foundation (ANR-18-IDEX-0001)
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-18-IDEX-0001)
- Fondation Leducq
- Institut National de la Santé et de la Recherche Médicale (UMS3655, ANR-18-IDEX-0001)
- Fondation pour la Recherche Médicale (ANR-18-IDEX-0001)
- Ligue Contre le Cancer (ANR-18-IDEX-0001)
- Centre National de la Recherche Scientifique (#ANR-18-IDEX-0001, UMS3655)
- Institut Universitaire de France (ANR-18-IDEX-0001)
- Institut National Du Cancer (#ANR-18-IDEX-0001)
- Institut Gustave-Roussy (UMS3655)
- European Research Area Network on Cardiovascular Diseases
- Weill Cornell Medical College
- Stand Up To Cancer (ZP-6177)
- High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
- Labex Immuno-Oncology ((ANR-18-IDEX-0001))
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- resiquimod, imidazoquinolines, TLR agonists, cancer immunotherapy, adjuvants, dendritic cell vaccine, DNA vaccine, peptide vaccine, preclinical and clinical trials
- MeSH terms
- Imiquimod, Adjuvants, Immunologic, Antineoplastic Agents, United States, Toll-Like Receptor 7, Toll-Like Receptor 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. https://app.cochat.ai/papers/10.1080/2162402x.2020.1796002
- The paper
- Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020). Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1796002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.